Tim Funnell

Tim Funnell is a seasoned professional in the biotechnology and venture capital sectors, currently serving as a Partner at Monograph Capital since June 2021, where the focus is on building transformative biotechnology companies. Additionally, Tim serves as Executive Director at Ascend Advanced Therapies and was the Founding CEO, driving the expansion of bespoke manufacturing services for innovative gene and cell therapy programs. Previous roles include Investor Director at Maxion Therapeutics and AviadoBio, and Trustee of OUTbio UK. Tim's earlier experience includes being part of the founding team at MiroBio Ltd, which was successfully sold to Gilead for $405M in 2022. Tim's educational background includes a DPhil in Pharmacology from the University of Oxford and a MA in Natural Sciences from the University of Cambridge.